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ABSTRACT
Imaging techniques are the standard method for assessment of fracture healing processes. However, 
these methods are perhaps not entirely reliable for early detection of complications, the most frequent of 
these being delayed union and non-union. A prompt diagnosis of such disorders could prevent prolonged 
patient distress and disability. Efforts should be directed towards the development of new technologies for 
improving accuracy in diagnosing complications following bone fractures. The variation in the levels of 
bone turnover markers (BTMs) have been assessed with regard to there ability to predict impaired fracture 
healing at an early stage, nevertheless the conclusions of some studies are not consensual. In this article 
the authors have revised the potential of BTMs as early predictors of prognosis in adult patients presenting 
traumatic bone fractures but who did not suffer from osteopenia or postmenopausal osteoporosis. The 
available information from the different studies performed in this field was systematized in order to 
highlight the most promising BTMs for the assessment of fracture healing outcome.
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regulatory proteins, non-union process.
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INTRODUCTION
The expected outcome of a fracture is the bone 
healing, defined as the functional stage of bone 
regeneration after a trauma, enabling the bone to 
acquire its anatomical and load-carrying properties, 
without additional assistance (Marsh and Li 1999). 
The expected time required for a complete and 
adequate fracture healing process depends on several 
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factors, such as the degree of injury of the adjacent 
soft tissue, the displacement of the fracture ends and 
the degree of comminution, the selected method for 
the stabilization of the fracture in addition to other 
patient related factors, namely the age of the patient 
and the presence of co-morbidities (diabetes, tobacco 
use, malnutrition and prolonged use of non-steroidal 
anti-inflammatory drugs) (Giannoudis et al. 2000, 
Buchwalter et al. 2010). It is estimated that 5-10% of 
all patients with long bone fractures should develop 
impaired fracture healing processes, especially 
delayed union and non-union processes. Delayed 
union corresponds to the pathological fracture healing 
process that takes almost twice the necessary length 
of time for the formation of the fracture callus, due to 
inadequate fracture stabilization and lack of patient 
rest as the most frequent causes of this complication. 
The development of a non-union process, the most 
commonly diagnosed fracture healing complication, 
corresponds to a failure of the fracture repair process 
(Marsh and Li 1999), generally due to extensive 
lesions of adjacent soft tissues and inadequate 
vascularisation of the trauma site (Court-Brown 
and McQueen 1987, Calori et al. 2007). The tibial 
fractures, due to the particularities of this bone, 
namely its blood supply and lack of muscle tissue on 
its anterior surface, present themselves as those most 
often affected by the phenomena of disturbances of 
the bone healing process, in which non-union occur 
in up to 10-20% of patients with tibial shaft fractures. 
In clinical practice, the fracture healing process is 
normally evaluated by physical and radiographic 
examinations. However, there is a lack of consensus 
in the assessment of this, rendering an estimation 
of the incidence of fracture healing complications 
difficult (Hernandez et al. 2012). The interpretation 
of radiographic signs of an impaired fracture 
healing process is subjective and the expected time 
span for their appearance is variable, so that the 
early diagnosis of fracture healing complications 
can prove difficult (Bishop et al. 2012). However, 
fracture healing complications are associated with 
prolonged pain and functional impairment, making 
the early diagnosis of such complications mandatory 
(Zimmermann et al. 2007, Buchwalter et al. 2010).
Serological bone turnover markers (BTMs) 
have been studied in fracture healing researches 
with the objective of monitoring the fracture 
callus development and have providing prognostic 
value for the early detection of fracture healing 
complications (Herrmann et al. 2002, Coulibaly 
et al. 2010, Cox et al. 2010). BTMs are products 
of bone cell activity and are generally subdivided 
into three categories: bone resorption markers, 
bone formation markers and osteoclast regulatory 
proteins (Leeming et al. 2006). The markers of 
bone resorption result from degradation of the 
type-I collagen such as the C-terminal telopeptide 
(CTX), the N-terminal telopeptide (NTX) of type-I 
collagen, the CTX – matrix metalloproteinase 
(ICTP), hydroxyproline (HYP), the collagen cross-
links [pyridinoline (PYD), deoxypyridinoline 
(DPD)], and the enzymes secreted by the 
osteoclasts, namely tartrate-resistant acid 
phosphatase (TRAP) 5b isoform (Cremers et al. 
2008). Bone formation markers derive from the 
osteoblastic activity, formed during the different 
stages of osteoblasts proliferation, differentiation 
and of osteoid synthesis (Aubin 2008, Cremers et 
al. 2008, Seibel 2000), namely the bone alkaline 
phosphatase (BALP), osteocalcin (OC), N-terminal 
propeptide (PINP) and C-terminal propeptide 
(PICP) of type-I procollagen (Cremers et al. 2008). 
Osteoclast regulatory proteins include the receptor 
activator of nuclear factor NF-κB ligand (RANKL) 
produced by osteocytes, osteoblasts and immune 
system cells, which are responsible for osteoclast 
activation, differentiation and survival (Li et al. 
2000, Teitelbaum and Ross 2003, Komori 2013) 
and also its membrane-bound receptor (RANK) 
in the osteoclast precursor cells (Asagiri and 
Takayanagi 2007). Osteoblastic, osteocytic and 
stromal cells also produce osteoprotegerin (OPG), 
which inhibits bone resorption by binding RANKL 
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(Khosla 2001, Theoleyre et al. 2004). The balance 
between the amount of OPG and RANKL regulates 
osteoclastic activity.
More recently, serum levels of growth factors, 
including transforming growth factor beta (TGF-β1) 
and bone morphogenetic proteins (BMPs) produced 
at the fracture site, have also been studied as non-
invasive tools in order to assess the fracture healing 
process (Zimmermann et al. 2005). Growth factors 
regulate the different steps of the cellular events that 
lead to normal bone union, from the initial haematoma 
to the final remodelling stage (Zimmermann et al. 
2005). Therefore, abnormal growth factor expression 
and release in the systemic circulation might be 
associated with impaired fracture healing processes.
The measurement of BTMs during the 
fracture healing process could enhance the 
accuracy of the bone healing stage assessment, 
allowing early detection in patients at risk of the 
development of fracture complications (Cox et al. 
2010), and enabling precocious treatment of these 
complications and prevention of prolonged patient 
distress and disability (Coulibaly et al. 2010). 
This study has aimed to investigate the clinical 
effectiveness of BTMs in monitoring the fracture 
healing process and identifying patients at risk of 
developing impaired fracture healing processes.
MATERIALS AND METHODS
Literature searches were undertaken on PubMed, 
ISI Web of Knowledge, Ebsco, Scopus and the 
US National Library of Medicine databases, by 
using a specific query. There was supplemented by 
a search of reference lists of the studies included 
and relevant reviews and by Internet searching in 
order to minimize publication bias. The base search 
strategy included the following components: (1) 
biological marker terms and (2) fracture healing 
terms. The paper selection process included a 
two-step approach in which the screening of title 
and abstract was followed by the application of 
inclusion criteria to the full paper of the selected 
studies. The inclusion criteria required that the 
studies: (1) should be conducted among adult 
patients who had undergone a traumatic fracture, 
(2) should be based on the application to BTMs in 
the follow-up of the fracture healing process, (3) 
should evaluate the fracture healing outcome, (4) 
should compare serum BTM levels in patients with 
a normal versus impaired fracture healing process. 
Inclusion was not restricted by date of publication 
or type of study. Studies conducted among elderly 
patients or patients suffering from osteopenia or 
postmenopausal osteoporosis were excluded from 
this review in order to minimize a confounding 
bias, since reduced bone mineral density could 
influence the bone fracture healing process. Studies 
were then analyzed according to the type of study 
and main issue covered and was classified in 
two groups of interest: (i) observational studies 
conducted in post-traumatized human and animal 
patients, and (ii) experimental studies.
RESULTS
As a result of the search, 2,528 papers were 
identified for initial screening. Of these, 43 were 
retrieved as full papers. Twenty one studies were 
later excluded because they were conducted 
amongst in osteoporotic or post-menopausal women 
with the aim of assessing the healing process after 
fragility fractures, manly hip, vertebral and femoral 
neck fractures. An additional seven studies were 
excluded because they didn´t compare serum 
BTM levels between a normal fracture healing 
process and an impaired fracture healing process. 
We included one abstract because no additional 
information was available and there was sufficient 
outcome data to extract (Fig. 1).
Table SI (Supplementary Material) summarizes 
the studies published, which report the value of 
BTMs in the early diagnosis of fracture healing 
disorders and their characteristics in terms of type 
of study, population and intervention. Tables II to 
IV summarize the main results published.
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TABLE II
Significance of bone formation biomarkers as early 
indicators of prognosis of bone healing process.
Authors Results 
ALP
Oni et al. (1989) No significant differences were observed between normal and impaired healing groups.
Komnenou et al. (2005)
In dogs with non-union process, the serum activity did not exceed the upper limit 
of reference during the study period. In dogs with normal fracture healing process, 
the serum activity was higher on 10th day after surgery than the normal reference 
interval (p<0.05).
Sousa et al. (2011) In normal healing group, the mean values of serum ALP were significantly higher than that of impaired healing group (p<0.05).
Singh Ajai et al. (2013)
In normal healing group, the mean values of serum ALP were significantly higher 
than that of impaired healing group. In non-union group, the mean serum ALP 
levels remained within normal limits throughout the entire follow-up.
BALP
Emami et al. (1999)
Patients with delayed healing process presented lower serum activity between 4th 
and 7th weeks after intramedullary nailing of tibial fractures than patients with 
normal fracture healing (p<0.05).
Herrmann et al. (2002) No significant differences between the two groups.
Southwood et al. (2003) Rabbits with osteomyelitis showed lower serum activity at 4
th post-operative week 
than rabbits with no infected fractures (p<0.05).
Klein et al. (2004) No significant differences between the two groups.
Marchelli et al. (2009) No significant differences between the two groups.
Sousa et al. (2011)
In dogs with normal fracture healing process, the serum activity was always 
higher during the follow-up after surgery than the normal reference interval 
measured in normal healthy dogs (p<0.05).
In the non-union group, the serum levels didn´t exceed the reference limits during 
the study period.
Moghaddam et al. (2011) No significant differences between the two groups.
OC
Oni et al. (1989) Patients with normal fracture healing presented higher serum levels compared with patients with delayed healing (p<0.05).
Emami et al. (1999) No significant differences between the two groups.
Herrmann et al. (2002)
Patients with normal fracture healing process presented an increase exceeding 
baseline levels at the 42nd day after traumatic fracture (p=0.034). In patients with 
delayed healing, serum levels began to increase 1 month later than patients with 
normal fracture healing process (28th day versus 60th day).
Southwood et al. (2003)
Rabbits with osteomyelitis showed lower serum levels at 4th post-operative week 
and higher serum levels at 16th week post-operative week than rabbits with no 
infected fractures (p<0.05).
Marchelli et al. (2009) No significant differences between the two groups.
PINP Moghaddam et al. (2011) No significant differences between the two groups.
PICP Klein et al. (2004) No significant differences between the two groups.
PIIINP
Kurdy (2000) PIIINP levels were significantly higher in delayed fracture healing at 10
th week 
after fracture than in normal fracture healing (p<0.05). 
Klein et al. (2004) No significant differences between the two groups.
ALP: Alkaline phosphatase; BALP: Bone specific alkaline phosphatase; OC: Osteocalcin; PINP: Amino-terminal procollagen 
propeptides of collagen type I; PICP: Carboxy-terminal procollagen propeptides of collagen type I; PIIINP: Amino-terminal 
procollagen propeptides of collagen type III.
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Authors Results
CTX
Herrmann et al. (2002) No significant differences between the two groups.
Moghaddam et al. (2011) Lower serum values at the 1
st week after surgery in delayed fracture healing process 
compared with normal bone union process (p=0.0164). 
ICTP Joerring et al. (1992) No significant differences between the two groups.
HYP Mukhopadhyay et al. (2011) Patients with proper union presented higher values of total and free urinary HYP at 3rd week after fracture than patients with impaired healing fractures.
PYD Emami et al. (1999) No significant differences between the two groups.
DPD
Southwood et al. (2003) Rabbits with osteomyelitis presented higher serum concentrations at 4
th, 8th and 16th 
post-operative weeks than rabbits with no infected fractures (p<0.05). 
Marchelli et al. (2009) No significant differences between the two groups.
TRAP 5b Moghaddam et al. (2011)
Relative serum concentration was decreased at the 2nd (p=0.0066) and 4th week after 
surgery (p=0.0043) in delayed fracture healing as compared to patients who have 
developed a normal fracture healing process.
CTX: Cross-linked C-terminal telopeptides of type I collagen; ICTP: Carboxy-terminal telopeptide of type I collagen; HYP: 
Hydroxyproline; DPD: Deoxypyridinoline; PYD: Pyridinoline; TRAP5b: Tartrate-resistant acid phosphatase isoenzyme 5b.
TABLE III
Significance of bone resorption biomarkers as early 
indicators of prognosis of bone healing process.
Authors Result
OPG Marchelli et al. (2009)
Patients with atrophic nonunion process of diaphyseal long bone fractures presented 
higher serum levels than control groups: subjects that have already healed from the 
same type of fracture (p<0.001) and subjects that were healing from the same type of 
fracture (p<0.001).
RANK 
Ligand Marchelli et al. (2009) No significant differences between the groups.
TGF-β1
Zimmermann et al. (2005) Four weeks after surgery, patients with delayed union process presented a significantly lower TGF-β1 concentration (p=0.002).
Sarahrudi et al. (2011) No significant differences between the groups.
BMP 
2,4,6,7,9 Baardewijk et al. (2013) No significant differences between the groups.
OPG: Osteoprotegerin; RANK: Receptor activator of nuclear factor NF-κB; TGF-β1: Transforming growth factor beta 1; 
BMP: Bone morphogenetic protein.
TABLE IV
Significance of osteoclasts regulatory proteins and growth factors 
as early indicators of prognosis of bone healing process.
DISCUSSION
In several studies it was demonstrated that serum 
and urinary BTMs are capable of reflecting the 
healing process with their levels dependent on the 
localization, type and size of the fracture (Laurer 
et al. 2000, Stoffel et al. 2007). Joerring et al. 
(1994) and Veitch et al. (2006) demonstrated that 
in patients with tibial shaft fractures the type of 
treatment, whether cast immobilization or surgical 
osteosynthesis methods, doesn’t produce significant 
differences in BTM levels.
Following a bone fracture an earlier increase 
in bone resorption markers generally occurs, with 
a posterior rise in bone formation markers (Veitch 
et al. 2006). Thus, at an initial stage after bone 
fracture a rise in collagenous degradation products 
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and osteoclast derived enzymes has been shown 
to occur (Joerring et al. 1994, Stoffel et al. 2007), 
probably due to the osteoclastic removal of the 
necrotic tissues at the fracture margins, a small 
segment of cortices at each side of the fracture 
(Fig. 2). This event is associated with an equivalent 
decrease in bone-formation markers (Bowles et 
al. 1996, Laurer et al. 2000, Stoffel et al. 2007), 
associated with an inhibition of osteoblastic 
synthesis activity which seems to be related to the 
release of cytokines by inflammatory cells (Laurer 
et al. 2000, Cox et al. 2010) (Fig. 2).
Figure 1 - Flow of studies through the review.
Figure 2 - Flow diagram of bone turnover markers and growth factors produced during the fracture 
healing process.
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Type-III collagen products, such as the amino-
terminal propeptide of type III procollagen (PIIINP), 
increase at this early stage during the endochondral 
fracture healing process and reach their maximal 
concentration in tibial shaft fractures by the 2nd 
week (Joerring et al. 1994) (Fig. 2). After this stage, 
a significant increase in bone formation markers 
has been demonstrated - that of the enzyme BALP 
and OC, since they were derived from osteoblast 
synthesis, produced during bone ECM mineralization 
and osteoblast maturation respectively (Obrant et al. 
1990, Bowles et al. 1996, Laurer et al. 2000), of type-I 
collagen products (Veitch et al. 2006, Stoffel et al. 
2007), and the persistence of high PIIINP levels, 
which are released during the formation as well as 
during the degradation of the fibrous tissue (Joerring 
et al. 1992, 1994) (Fig. 2). Stoffel et al. (2007) and 
Veitch et al. (2006) verified that in patients with tibial 
fractures, after bone union is achieved, the bone 
resorption markers and bone formation markers remain 
augmented, corresponding to the remodelling stage 
of the bone healing process. Stoffel et al. (2007) also 
demonstrated that the normalization of PIIINP levels 
precedes radiographic evidence of bone union. Despite 
serum BTM levels possibly being associated with the 
different stages of the bone fracture healing process, 
their clinical effectiveness in predicting impaired 
fracture healing processes at an early stage isn’t clear.
In a study performed by Komnenou et al. 
(2005) on dogs, and in one performed by Singh 
Ajai et al. (2013) on human patients, the serum 
alkaline phosphatase (ALP) activity was determined 
throughout the healing process of long bone 
diaphyseal fractures. In both studies it was observed 
that serum ALP activity remained within the reference 
limits during the entire postoperative period in patients 
that had developed a non-union process, probably 
indicating a suppression of osteoblastic activity. Singh 
Ajai et al. (2013) also observed significantly higher 
levels of serum ALP activity in the group of patients 
that presented a normal bone union as compared with 
the delayed healing group. The serum levels of ALP 
are the sum of four isoenzymes: intestinal, placental, 
liver and bone. The bone (BALP) and liver isoforms 
represent the most relevant fraction of total ALP 
activity, with an almost equal contribution to about 
95% of this enzyme. In the absence of pregnancy and 
liver or intestinal disorder, ALP activity could be an 
inexpensive marker for monitoring the bone fracture 
healing process.
As regards the bone specific isoform-BALP, 
Emami et al. (1999) found lower levels in patients 
with delayed union at an early time point during 
the fracture healing process (by the 4th week after 
the fracture occurrence) than patients with a normal 
bone union. Similar results were found from a small 
study conducted on animals (Sousa et al. 2011). 
Nevertheless, these results are not in accordance 
with those obtained from further research conducted 
by Herrmann et al. (2002), Marchelli et al. (2009) 
and Moghaddam et al. (2011), BALP activity being 
shown to be incapable of predicting bone fracture 
healing outcome, because in these latter studies no 
significant differences in serum BALP activity were 
found during the healing process in either patient 
groups. In these latter studies serum BALP activity, 
rather than its concentration, was found, this being 
a more reliable indicator of osteoblastic activity.
In a study performed by Oni et al. (1989) 
on patients with fractures of the tibial diaphysis 
stabilized by conservative methods, and in a 
following study performed by Herrmann et al. 
(2002) on patients with tibial or femoral shaft 
fractures stabilized by osteosynthesis techniques, the 
serial measurement of serum OC concentration was 
a valid aid in the early detection of patients at risk 
of developing a delayed union, probably reflecting 
disturbances in bone remodelling. However, the 
results obtained differed, which could be explained 
by the different study design. In the first study, lower 
OC concentrations were reported in the group of 
patients whose fractures evolved into delayed union 
than in the group showing normal bone union, from 
the first days after treatment and throughout the 
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entire study period, while in the second study there 
was a lag in the rise of OC concentration during the 
first 2 months amongst the group of patients that 
underwent a delayed union. Nevertheless, Emami 
et al. (1999) and Marchelli et al. (2009) found that 
serum OC concentration was unable to differentiate 
between a delayed union and a normal bone union. 
These studies present some limitations that could call 
into question the comparability of the results from 
the different study groups, results which are mainly 
related to the small number of patients included in 
each group. Additionally, the work conducted by 
Marchelli et al. (2009) is a cross-sectional study, 
rather than a prospective study like all the others 
studies, in which the levels of BTMs from three 
groups of patients at different time points in the 
fracture healing process were compared.
An evaluation of the serum PINP levels derived 
from a collagen molecule revealed no differences 
between patients who, after undergoing a traumatic 
fracture, progressed into a non-union or a normal 
bone union (Moghaddam et al. 2011), whereas PICP 
serum levels were higher in patients with delayed 
fracture healing by the 2nd week after fracture than 
in patients undergoing a normal fracture healing 
process (p=0.07) (Joerring et al. 1994). However, 
extrapolating the conclusions of this work should 
be done with some caution due to the small number 
of patients that the study groups comprised.
Kurdy (2000) found significantly higher serum 
PIIINP concentrations in patients with delayed union 
than in patients who were undergoing an adequate 
fracture healing process. This correlates well with 
previous histological findings in relation to non-union 
fractures (Lawton et al. 1997). In the normal fracture 
healing process it was observed that the expression 
of collagen type-III is restricted to an early stage 
during bone regeneration and produced by MSCs and 
fibroblastic cells, while impaired healing fractures 
showed prolonged high amounts of collagen type-
III also produced by mature osteoblasts which were 
located on woven bone surfaces (Lawton et al. 1997).
Emami et al. (1999) observed that patients 
with delayed healing did not differ in cross-linked 
telopeptides, namely serum PYD levels, when 
compared with patients with normal fracture 
healing. In a study, Moghaddam et al. (2011) 
observed that patients with delayed fracture healing 
presented lower serum CTX values early in the 
postoperative period than patients with normal bone 
union. Analogous results were found for total and 
free urinary HYP, with initially lower levels after 
the fracture in patients with impaired bone healing 
(Mukhopadhyay et al. 2011). The overall role 
of TRAP 5b as a prognostic indicator of fracture 
healing was also assessed, and the authors observed 
lower serum TRAP 5b activity at early stages 
in patients with delayed fracture healing than in 
patients who had presented normal fracture healing, 
probably reflecting disturbances in bone resorption 
during the normal process of bone regeneration 
(Moghaddam et al. 2011). This is the only research 
available that addresses the role of TRAP 5b in the 
early detection of fracture healing disturbances, 
the results presented justifying undertaking further 
research based on a larger population. As regards 
other issues, TRAP 5b proved to be one of the most 
promising markers of bone resorption, being very 
sensitive and specific and capable of detecting early 
bone metastases (Halleen 2003), predicting the 
occurrence of fractures (Gerdhem et al. 2004) and 
diagnosing aseptic loosening of hip arthroplasty 
(Landgraeber et al. 2010).
With regard to molecules that regulate the 
function of osteoclasts, a preliminary clinical study 
was conducted in which differences were observed 
in serum OPG levels between patients who had 
developed an atrophic non-union and those that 
had progressed towards normal fracture healing 
(Marchelli et al. 2009). However, in a more recent 
study, it was noticed that in patients with a normal 
bone-union, serum OPG, RANK and RANKL 
levels were not affected by the fracture healing 
process, since these levels remained unchanged 
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during the period of time under consideration 
(Colombini et al. 2011).
Zimmermann et al. (2005) and Sarahrudi et al. 
(2011) compared the serological levels of TGF-β1 
after bone fracture in patients with normal and 
impaired fracture healing, but obtained different 
results. Zimmermann et al. (2005) verified that the 
serological variation of TGF-β1 could contribute to 
an early detection of an impaired fracture healing 
process. However, in a more recent research 
conducted by Sarahrudi et al. (2011) no differences 
were found between these groups. Similar results 
were obtained by Baardewijk et al. (2013), when 
the differences in the serum levels of BMP-2, 4, 
6, 7 and 9 in patients with impaired and normal 
fracture healing process were compared.
Southwood et al. (2003) developed a non-union 
model in rabbits by injecting Staphylococcus aureus 
into femoral fracture defects, and compared serum 
BTM levels in this group with levels obtained in 
a group of animals undergoing a normal fracture 
healing process. The measurement of serum BALP 
activity and OC and DPD levels was demonstrated to 
be effective for the assessment of the fracture healing 
process and for the early diagnosis of osteomyelitis, 
since the authors confirmed lower serum levels of 
BALP and OC and higher serum levels of DPD in 
the non-union group by the 4th postoperative week 
than in the non-infected control group.
In an experimental research conducted on sheep, 
a standardized midshaft osteotomy of the tibia was 
performed, the tibia being stabilized with either a 
unilateral external fixator or an unreamed tibial nail 
locked with mediolateral inserted bolts (Klein et al. 
2004). During the healing process, interfragmentary 
movements and axial torsion was significantly 
higher in the group stabilized by means of the 
tibial nail than in the group with external fixators. 
Therefore, since the degree of stability at the bone 
ends determines the progression of fracture healing, 
the groups presented different healing evolutions, 
with the first group showing a delayed union 
compared to the second group. Despite differences 
in the level of fracture callus consolidation, the 
BTMs were not sufficiently sensitive to detect 
changes in the healing process and there were no 
significant differences observed in the biomarkers 
studied, that is serum BALP activity and serum PICP 
and PIIINP levels (Klein et al. 2004). Nevertheless, 
regarding the limitations of experimental studies 
and in comparison to clinical situations, the 
observed delayed fracture healing could not entirely 
demonstrate the pathophysiological mechanisms 
underlying an impaired healing process.
The main limitation for the clinical application of 
BTMs in patients is related to a remarkable biological 
variability, rendering it difficult to establish normal 
limits of serum and urinary BTM levels which are 
required for clinical application (Souberbielle et al. 
1999). Many biological factors cannot be controlled, 
such as age, gender and ethnicity, the comparison of 
the results with reference intervals created for these 
factors being mandatory (Seibel 2005). Besides 
these, most of the biochemical markers also show a 
circadian rhythm with a coefficient of variation that 
can reach 60%. The circadian rhythm is particularly 
marked in BTMs measured in urine, presenting 
higher values in the morning and lower values in the 
evening and at night. The only known factor which 
significantly influences this circadian variation is 
fasting, which can reduce the range of variation by 
25%, if samples are collected in the morning before 
feeding and after 12 hours of fasting (Schlemmer and 
Hassager 1999, Clowes et al. 2002, Qvist et al. 2002). 
Hence, controlling the timing of sampling is crucial 
in order to obtain results with clinical significance 
(Seibel 2006).
Regarding the conditions that contribute to the 
analytical variability, it is worth pointing out that 
some BTMs are susceptible to thermodegradation, 
photolysis or haemolysis, which can lead to the 
consumption of these molecules, if proper collection 
and environmental conditions for sampling, handling 
and processing are not guaranteed. Generally, a 
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temperature of -70°C for serum samples and -30°C for 
urinary samples is recommended for storage (Seibel 
2006). Additionally, BTMs are affected by freeze-
thaw cycles, which should be avoided by separating 
the samples in different vials, when it is necessary 
to perform several assays. The reproducibility of the 
results thus depends on the standardization of sample 
processing and preservation in order to ensure their 
stability (Seibel 2000). Another obstacle to ensuring 
reproducibility of the results is related to a high inter-
laboratory variability. It was demonstrated that results 
obtained from identical samples and determined 
by means of the same analytical method may have 
a coefficient of variation exceeding 48%, thereby 
hampering the comparison of the results between 
different laboratories (Seibel et al. 2001).
CONCLUSIONS
The need for an accurate outcome measurement 
in fracture healing has been emphasized. The 
changes in BTM levels and their capacity to 
predict impaired fracture healing processes were 
discussed by several authors, but it is difficult to 
achieve consensus. The evidence that is available 
was heterogeneous, thus making it difficult to draw 
conclusions as to whether or not BTMs were able 
to identify patients at risk of developing impaired 
fracture healing processes.
One of the major limitations of some of these 
studies is the loss of statistical power due to the 
inclusion of only a small number of participants, 
which comprises the external validity of the studies 
undertaken up to the present. Moreover, even if we 
control the listed issues that contribute to biological 
and analytical variability, in order to understand 
the value of BTMs as prognostic indicators in 
the bone healing process it would be necessary to 
carry out more observational studies involving the 
elimination of additional factors that may influence 
the serum levels in patients with bone fractures. 
Thus, since the amount of fracture callus formation 
could differ depending on the type[s] of fracture, on 
osteosynthesis methods and fracture localization, 
in order to exclude the influence of these possibly 
confusing factors, such issues should be used 
to match patients of the different study groups, 
those with normal and impaired fracture healing 
processes, during the study design and statistical 
analysis of the results. However, it is worth noting 
that the exact match is difficult to achieve in 
observational studies.
At the present time, there is evidence that 
supports the undertaking of further studies using an 
adequate number of patients and appropriate study 
design, since in several studies the BTMs were 
suitable for discriminating between normal and 
impaired fracture healing processes at an early point 
in time. Impaired healing fractures are associated 
with abnormally high amounts of collagen type-III 
expressed by osteoblasts on woven bone surfaces, 
which are correlated with elevated serum PIIINP 
levels observed in patients at an early stage. These 
findings suggest that serum PIIINP levels can be 
a promising marker for the detection of fracture 
healing disturbances.
The importance of osteoclast regulatory proteins, 
namely OPG, RANK and RANKL, as prognostic indi-
cators in fracture healing, is relatively unrecognized. 
Additional studies are needed to verify the potential of 
these markers for predicting the evolution of traumatic 
bone fractures after their treatment.
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RESUMO
As técnicas imagiológicas são o método convencional 
para a avaliação dos processos de cicatrização das fraturas. 
No entanto, estes métodos não são talvez totalmente 
confiáveis para a deteção precoce de complicações, as mais 
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frequentes destas sendo o atraso da união e a não-união. 
Um diagnóstico eficaz destas desordens poderia prevenir 
a dor e a incapacidade prolongada do paciente. Esforços 
devem ser dirigidos no sentido do desenvolvimento de 
novas tecnologias para melhorar a exatidão no diagnóstico 
de complicações após fraturas ósseas. A variação nos 
níveis dos marcadores do turnover ósseo (BTMs) têm 
sido avaliados com vista à sua capacidade para prever 
o comprometimento da cicatrização das fraturas numa 
fase inicial, no entanto, as conclusões de alguns estudos 
não são consensuais. Neste artigo os autores fizeram 
uma revisão do potencial dos BTMs como fatores de 
previsibilidade precoce do prognóstico em doentes adultos 
que apresentavam fraturas ósseas traumáticas mas que não 
sofriam de osteopenia ou osteoporose pós-menopausa. 
A informação disponível nos diferentes estudos realizados 
neste campo foi sistematizada com vista a evidenciar-se os 
BTMs mais promissores para a avaliação da evolução da 
cicatrização das fraturas.
Palavras-chave: marcadores de formação óssea, 
marcadores de reabsorção óssea, atraso da união, 
cicatrização das fraturas, proteínas reguladoras de 
osteoclastos, processo de não-união.
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SUPPLEMENTARY MATERIAL
TABLE SI - Characteristics of the studies that assess the 
role of BTMs in predicting the prognosis of bone fracture 
healing. ALP: Alkaline phosphatase; BALP: Bone specific 
alkaline phosphatase; OC: Osteocalcin; PINP: Amino-terminal 
procollagen propep tides of collagen type I; PICP: Carboxy-
terminal procollagen propeptides of collagen type I; PIIINP: 
Amino-terminal procollagen propeptides of collagen type III; 
CTX: Cross-linked C-terminal telopeptides of type I collagen; 
ICTP: Carboxy-terminal telopeptide of type I collagen; HYP: 
Hydroxyproline; DPD: Deoxypyridinoline; PYD: Pyridinoline; 
ICTP: Carboxy-terminal telopeptide of type I collagen; 
TRAP5b: Tartrate-resistant acid phosphatase isoenzyme 5b; 
OPG: Osteoprotegerin; RANK: Receptor activator of nuclear 
factor NF-κB; TGF-β1: Transforming growth factor beta 1; 
BMP: Bone morphogenetic protein; ELISA: Enzyme-Linked 
Immunosorbent Assay; RIA: Radioimmunoassay; ECLIA: 
Electrochemiluminescent Immunoassays; CLIA: Chemilumi-
nescent Immunoassay; EAA: Enzyme Activity Assay.

